Mobile Mindfulness Training (mMT) for People in Medication Treatment of Opioid Use Disorder (MOUD)

Launched by AMY MEADOWS · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial, called the Pilot Mobile Mindfulness Training (mMT) for People in Medication Treatment of Opioid Use Disorder, is exploring whether using a mobile app for mindfulness training can help individuals who are being treated for opioid use disorder, especially those with a history of childhood trauma. The main goal is to find out if participants will use the app and if it can help reduce their stress levels.

To be eligible for this study, participants need to be diagnosed with opioid use disorder and currently receiving treatment at a clinic associated with UKHealthCare or the University of Kentucky. They should have a stable dose of certain medications (like buprenorphine) for at least 30 days and have experienced childhood trauma. Participants will access the mindfulness app and are encouraged to use it daily for 30 days while keeping a diary of their usage. They will also visit the clinic four times to check their stress levels through questionnaires, blood tests, and heart rate measurements. This study is not yet recruiting participants, but it aims to gather valuable information on how mindfulness training can support recovery from opioid use disorder.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinically diagnosed with Opioid Use Disorder (per DSM5 criteria)
• • Currently enrolled in treatment for Opioid Use Disorder at a clinic affiliated with UKHealthCare or University of Kentucky
• • On a stable dose of buprenorphine, buprenorphine/naloxone, or naloxone (i.e., at least 30 days post-induction and on a stable dose for 30 days)
• • Able to read and understand English
• • Have a history of childhood trauma as measured by the Adverse Childhood Experiences scale and/or Childhood Trauma Questionnaire.
• Exclusion Criteria:
• • Currently taking a beta-blocker, calcium-channel blocker, antiarrhythmic, corticosteroid, or immune modulator medication
• • Uncontrolled acute or chronic health conditions (e.g., active infections, autoimmune conditions, cancer undergoing active treatment)
• • Current or expected pregnancy
• • Current mindfulness practice (i.e., participant reports practicing mindfulness for 10 minutes or more per week)
• • Primary psychotic illness
• • Diagnosis of a disorder known to interfere with neurocognitive function (e.g., estimated full scale IQ below 70 or diagnosis of dementia)